发明名称 IN VIVO HALF LIFE INCREASED FUSION PROTEIN OR PEPTIDE MAINTAINED BY SUSTAINED IN VIVO RELEASE, AND METHOD FOR INCREASING IN VIVO HALF-LIFE USING SAME
摘要 <p>The present invention relates to a fusion protein or peptide, the in vivo half-life of which is increased by maintaining in vivo sustained release, and to a method for increasing in vivo half-life using same. A fusion protein or peptide according to the present invention has excellent in vivo stability by bindinga physiologically active protein or physiologically active peptide to an alpha-1 antitrypsin or alpha-1 antitrypsin mutant with one or more amino acids mutated to maintain the in vivo sustained release and to significantly increase the half-life thereof in blood (T1/2) compared to an inherent physiologically active protein or physiologically active peptide. Thus, a fusion protein or peptide according to the present invention can be useful in developing a sustained-release preparation of a protein or peptide drug.</p>
申请公布号 EP2423233(B1) 申请公布日期 2015.03.11
申请号 EP20100767304 申请日期 2010.04.22
申请人 ALTEOGEN, INC 发明人 CHUNG, HYE SHIN;YOO, SEUNG BUM;LEE, SANG MEE
分类号 C07K19/00;C07K14/475;C07K14/81 主分类号 C07K19/00
代理机构 代理人
主权项
地址